Image Parkinson's Disease Progression Study

PHASE2CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

May 11, 2023

Study Completion Date

May 11, 2023

Conditions
Parkinson's Disease
Interventions
DRUG

Rasagiline

Rasagiline will be taken for one year at the dose of 1mg a day. and subjects will undergo functional and structural brain imaging to determine if rasagiline is slowing the progression of Parkinson's Disease in the brain.

OTHER

Placebo

A placebo tablet will be taken for one year, once a day, and at the same dose of 1mg. subjects will undergo functional and structural brain imaging to be compared with the group taking the rasagiline intervention.

DEVICE

Magnetic Resonance Imaging

This test will be performed at baseline and one year.

DEVICE

functional Magnetic Resonance Imaging

This test will be performed at baseline and one year.

OTHER

Physical Function Performance Test

This test will be performed at baseline and one year.

Trial Locations (1)

32611

Laboratory for Rehabilitation Neuroscience, Gainesville

All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

University of Florida

OTHER

NCT02789020 - Image Parkinson's Disease Progression Study | Biotech Hunter | Biotech Hunter